Shanghai Junshi Announces Chinese Adalimumab Approval
Partnered With Mabwell On Biosimilar Rival To Humira
Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.
You may also be interested in...
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.
After receiving approval from the Chinese regulatory body for rituximab and trastuzumab, Shanghai Henlius Biotech has now received approval for its HLX03 adalimumab biosimilar rival to Humira. The company has partnered with Wanbang Biopharma for commercialization of HLX03 in China.
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.